317 related articles for article (PubMed ID: 33477279)
1. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
Uotani K; Tazawa H; Hasei J; Fujiwara T; Yoshida A; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Kondo H; Morita T; Kiyono M; Yokoo S; Hata T; Kunisada T; Takeda K; Urata Y; Fujiwara T; Ozaki T
PLoS One; 2024; 19(2):e0298292. PubMed ID: 38377118
[TBL] [Abstract][Full Text] [Related]
4. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
Fujiwara T; Tanaka N
Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
7. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Tanaka N
Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
[TBL] [Abstract][Full Text] [Related]
8. [Oncolytic virotherapy for human solid tumors].
Fujiwara T
Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
[TBL] [Abstract][Full Text] [Related]
9. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
10. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
12. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases.
Yano S; Tazawa H; Hashimoto Y; Shirakawa Y; Kuroda S; Nishizaki M; Kishimoto H; Uno F; Nagasaka T; Urata Y; Kagawa S; Hoffman RM; Fujiwara T
Clin Cancer Res; 2013 Dec; 19(23):6495-505. PubMed ID: 24081978
[TBL] [Abstract][Full Text] [Related]
14. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
15. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
Fujiwara T; Urata Y; Tanaka N
Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
[TBL] [Abstract][Full Text] [Related]
17. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
18. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Urata Y; Tanaka N
Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
Fujiwara T; Kagawa S; Tazawa H
Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]